Name | Value |
---|---|
Revenues | 11.8M |
Cost of Revenue | 1.7M |
Gross Profit | 10.1M |
Operating Expense | 24.5M |
Operating I/L | -14.4M |
Other Income/Expense | -4.5M |
Interest Income | 0.7M |
Pretax | -18.8M |
Income Tax Expense | -0.2M |
Net Income/Loss | -18.7M |
OptiNose, Inc. is a specialty pharmaceutical company that develops and commercializes products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company's flagship product, XHANCE, utilizes a proprietary exhalation delivery system to deliver a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. Additionally, it offers Onzetra Xsail, a powder EDS device, and is developing OPN-019, which combines a liquid EDS device with an antiseptic. OptiNose generates revenue through the sale and commercialization of these therapeutic products.